Current progress, challenges and future prospects of diagnostic and therapeutic interventions in Alzheimer's disease

The amyloid hypothesis of Alzheimer's disease at 25 years

Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164

Development of Virus-Like Particle Technology from Small Highly Symmetric to Large Complex Virus-Like Particle Structures

Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975

Anti-Vascular Endothelial Growth Factors Protect Retinal Pigment Epithelium Cells Against Oxidation by Modulating Nitric Oxide Release and Autophagy

Cillà, S. D., Farruggio, S., Vujosevic, S., Raina, G., Filippini, D. A., Gatti, V., Clemente, N., Mary, D., Vezzola, D., Casini, G., et al. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000479441 · Cited by 5,154

2016 Alzheimer's disease facts and figures

Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069

The global prevalence of dementia: a systematic review and metaanalysis.

Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941

Inflammation and Alzheimer’s disease

Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496

The Alzheimer’s disease neuroimaging initiative (ADNI): MRI methods

Jack, C. R., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., Borowski, B., Britson, P. J., L. Whitwell, J., Ward, C., et al. (2008) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.21049 · Cited by 4,347

Autophagy: cellular and molecular mechanisms

Glick, D. R., Barth, S., & Macleod, K. F. (2010) · The Journal of Pathology · doi:10.1002/path.2697 · Cited by 3,995

Protein aggregation and neurodegenerative disease

Ross, C. A., & Poirier, M. A. (2004) · Nature Medicine · doi:10.1038/nm1066 · Cited by 3,454

Oxidative stress: a concept in redox biology and medicine

Sies, H. (2015) · Redox Biology · doi:10.1016/j.redox.2015.01.002 · Cited by 3,208

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059

The cholinergic hypothesis of Alzheimer’s disease: A review of progress

Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198

Untitled work

Bloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194

Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.

Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,142

CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis

Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049

Alzheimer Mechanisms and Therapeutic Strategies

Huang, Y., & Mucke, L. (2012) · Cell · doi:10.1016/j.cell.2012.02.040 · Cited by 1,758

Alzheimer's Disease and the Amyloid-β Peptide

Murphy, M. P., & LeVine, H. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-1221 · Cited by 1,750

High performance plasma amyloid-β biomarkers for Alzheimer's disease

Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681

Proliferation of amyloid-β42 aggregates occurs through a secondary nucleation mechanism

Cohen, S. I. A., Linse, S. S., Luheshi, L. M., Hellstrand, E., White, D. A., Rajah, L., Otzen, D. E., Vendruscolo, M., Dobson, C. M., & Knowles, T. P. J. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218402110 · Cited by 1,450

Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice

Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447

Oxidative stress, mitochondrial damage and neurodegenerative diseases.

Guo, C., Sun, L., Chen, X., & Zhang, D. (2013) · PubMed · doi:10.3969/j.issn.1673-5374.2013.21.009 · Cited by 1,371

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224

Tau in Alzheimer Disease and Related Tauopathies

Iqbal, K., Liu, F., Gong, C., & Grundke, I. (2010) · Current Alzheimer Research · doi:10.2174/156720510793611592 · Cited by 1,163

The Cholinergic Hypothesis of Age and Alzheimer’s Disease-Related Cognitive Deficits: Recent Challenges and Their Implications for Novel Drug Development

Terry, A. V., & Buccafusco, J. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.041616 · Cited by 1,159

Microglial priming in neurodegenerative disease

Perry, V. H., & Holmes, C. (2014) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.38 · Cited by 1,127

Role of Glutamate and NMDA Receptors in Alzheimer’s Disease

Wang, R., & Reddy, P. H. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160763 · Cited by 1,009

Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature

Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975

Arrest of -Amyloid Fibril Formation by a Pentapeptide Ligand

Tjernberg, L. O., Näslund, J., Lindqvist, F., Johansson, J., Karlström, A. R., Thyberg, J., Terenius, L., & Nordstedt, C. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.15.8545 · Cited by 963

The Amyloid Beta Peptide: A Chemist’s Perspective. Role in Alzheimer’s and Fibrillization

Hamley, I. W. (2012) · Chemical Reviews · doi:10.1021/cr3000994 · Cited by 892

Brain Imaging in Alzheimer Disease

Johnson, K. A., Fox, N. C., Sperling, R. A., & Klunk, W. E. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006213 · Cited by 875

Anatomy and physiology of cerebrospinal fluid

Sakka, L. J., Coll, G., & Chazal, J. (2011) · European Annals of Otorhinolaryngology Head and Neck Diseases · doi:10.1016/j.anorl.2011.03.002 · Cited by 816

P1‐146: Chlamydia Pneumoniae‐Infected Astrocytes Alter Their Expression of Adam10, Bace1, and Presenilin‐1 Proteases

Al-Atrache, Z., Cader, A., & Appelt, D. M. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.894 · Cited by 765

In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18 F-AV-45 (Flobetapir F 18)

Wong, D. F., Rosenberg, P. B., Zhou, Y., Kumar, A., Raymont, V., Ravert, H. T., Dannals, R. F., Nandi, A., Brašić, J. R., Ye, W., et al. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069088 · Cited by 684

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602

Therapeutics for Alzheimer's Disease Based on the Metal Hypothesis

Bush, A. I., & Tanzi, R. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.001 · Cited by 582

Towards an understanding of amyloid-β oligomers: characterization, toxicity mechanisms, and inhibitors

Lee, S. J. C., Nam, E., Lee, H. J., Savelieff, M. G., & Lim, M. H. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00731g · Cited by 576

Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo

Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574

Alzheimer's disease drug development pipeline: 2017

Cummings, J., Lee, G., Mortsdorf, T., Ritter, A., & Zhong, K. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.05.002 · Cited by 549

Peptidomimetics, a synthetic tool of drug discovery

Vágner, J., Qu, H., & Hruby, V. J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.03.009 · Cited by 542

Biological metals and metal-targeting compounds in major neurodegenerative diseases

Barnham, K. J., & Bush, A. I. (2014) · Chem. Soc. Rev. · doi:10.1039/c4cs00138a · Cited by 497

Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils

Bieschke, J., Herbst, M., Wiglenda, T., Friedrich, R. P., Boeddrich, A., Schiele, F., Kleckers, D., del Amo, J. M. L., Grüning, B. A., Wang, Q., et al. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.719 · Cited by 452

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients

Kennedy, M. E., Stamford, A. W., Chen, X., Cox, K., Cumming, J. N., Dockendorf, M. F., Egan, M. F., Ereshefsky, L., Hodgson, R. A., Hyde, L. A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad9704 · Cited by 441

Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab

Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431

Drug candidates in clinical trials for Alzheimer’s disease

Hung, S.-Y., & Fu, W.-M. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0355-7 · Cited by 420

Untangling Amyloid-β, Tau, and Metals in Alzheimer’s Disease

Savelieff, M. G., Lee, S., Liu, Y., & Lim, M. H. (2013) · ACS Chemical Biology · doi:10.1021/cb400080f · Cited by 407

Antioxidant Therapies for Alzheimer's Disease

Feng, Y., & Wang, X. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/472932 · Cited by 393

Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease

Coric, V., van Dyck, C. H., Salloway, S., Andreasen, N., Brody, M., RICHTER, R. W., Soininen, H. S., Thein, S., Shiovitz, T. M., Pilcher, G. D., et al. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.2194 · Cited by 374

Misfolded proteins in Alzheimer's disease and type II diabetes

DeToma, A. S., Salamekh, S., Ramamoorthy, A., & Lim, M. H. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15112f · Cited by 363

Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology

Schilling, S., Zeitschel, U., Hoffmann, T., Heiser, U., Francke, M., Kehlen, A., Holzer, M., Hutter-Paier, B., Prokesch, M., Windisch, M., et al. (2008) · Nature Medicine · doi:10.1038/nm.1872 · Cited by 357

Pyrrolidine constrained bipyridyl-dansyl click fluoroionophore as selective Al3+sensor

Maity, D., & Govindaraju, T. (2010) · Chemical Communications · doi:10.1039/c0cc00119h · Cited by 346

Structure-based inhibitors of tau aggregation

Seidler, P. M., Boyer, D. R., Rodríguez, J. A., Sawaya, M. R., Cascio, D., Murray, K. A., Gonen, T., & Eisenberg, D. S. (2017) · Nature Chemistry · doi:10.1038/nchem.2889 · Cited by 346

A differentially selective sensor with fluorescence turn-on response to Zn 2+ and dual-mode ratiometric response to Al 3+ in aqueous media

Maity, D., & Govindaraju, T. (2011) · Chemical Communications · doi:10.1039/c1cc16064h · Cited by 331

The Revitalized Tau Hypothesis on Alzheimer's Disease

Maccioni, R. B., Farias, G. A., Morales, I., & Navarrete, L. P. (2010) · Archives of Medical Research · doi:10.1016/j.arcmed.2010.03.007 · Cited by 316

Amyloid‐Beta Interaction with Mitochondria

Pagani, L., & Eckert, A. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/925050 · Cited by 309

Multi-Method Analysis of MRI Images in Early Diagnostics of Alzheimer's Disease

Wolz, R., Julkunen, V., Koikkalainen, J. R., Niskanen, E. I., Zhang, D. P., Rueckert, D., Soininen, H. S., Lötjönen, J. M. P., & Initiative, T. A. D. N. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025446 · Cited by 296

A Review of Fluid Biomarkers for Alzheimer’s Disease: Moving from CSF to Blood

Blennow, K. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0073-9 · Cited by 295

Peptidomimetics via modifications of amino acids and peptide bonds

Avan, İ., Hall, C. D., & KATRITZKY, A. R. (2014) · Chemical Society Reviews · doi:10.1039/c3cs60384a · Cited by 285

Mechanism of NMDA receptor channel block by MK-801 and memantine

Song, X., Jensen, M. Ø., Jogini, V., Stein, R. A., Lee, C.-H., Mchaourab, H. S., Shaw, D. E., & Gouaux, E. (2018) · Nature · doi:10.1038/s41586-018-0039-9 · Cited by 275

The Role of Cdk5 in Alzheimer’s Disease

Liu, S., Wang, C., Jiang, T., Tan, L., Xing, A., & Yu, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9369-x · Cited by 274

Non-invasive assessment of Alzheimer’s disease neurofibrillary pathology using 18F-THK5105 PET

Okamura, N., Furumoto, S., Fodero‐Tavoletti, M. T., Mulligan, R. S., Harada, R., Yates, P. A., Pejoska, S., Kudo, Y., Masters, C. L., Yanai, K., et al. (2014) · Brain · doi:10.1093/brain/awu064 · Cited by 273

Metal Ions and Intrinsically Disordered Proteins and Peptides: From Cu/Zn Amyloid-β to General Principles

Faller, P., Hureau, C., & Penna, G. L. (2014) · Accounts of Chemical Research · doi:10.1021/ar400293h · Cited by 271

Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy

Zotova, E., Nicoll, J. A. R., Kalaria, R. N., Holmes, C., & Boche, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt24 · Cited by 269

Efficient Inhibition of the Alzheimer's Disease β-Secretase by Membrane Targeting

Rajendran, L., Schneider, A., Schlechtingen, G., Weidlich, S., Ries, J., Braxmeier, T. M., Schwille, P., Schulz, J. B., Schroeder, C., Simons, M., et al. (2008) · Science · doi:10.1126/science.1156609 · Cited by 266

First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model

Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 266

Etanercept in Alzheimer disease

Butchart, J., Brook, L., Hopkins, V., Teeling, J. L., Püntener, U., Culliford, D. J., Sharples, R., Sharif, S., McFarlane, B., Raybould, R., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001617 · Cited by 260

Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy

Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease

Salloway, S., Sperling, R., Keren, R., Porsteinsson, A. P., van Dyck, C. H., Tariot, P. N., Gilman, S., Arnold, D., Abushakra, S., Hernandez, C., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e3182309fa5 · Cited by 258

Proinflammatory cytokines, sickness behavior, and Alzheimer disease

Holmes, C., Cunningham, C. M., Zotova, E., Culliford, D. J., & Perry, V. H. (2011) · Neurology · doi:10.1212/wnl.0b013e318225ae07 · Cited by 250

Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib

Domı́nguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 249

Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease

Rajasekhar, K., Chakrabarti, M., & Govindaraju, T. (2015) · Chemical Communications · doi:10.1039/c5cc05264e · Cited by 243

Mitochondria-Specific Accumulation of Amyloid β Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death

Cha, M.-Y., Han, S.-H., Son, S. M., Hong, H., Choi, Y.-J., Byun, J., & Mook‐Jung, I. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034929 · Cited by 236

Design, Synthesis, and Evaluation of Multitarget-Directed Resveratrol Derivatives for the Treatment of Alzheimer’s Disease

Lu, C., Guo, Y., Yan, J., Luo, Z., Luo, H., Yan, M., Huang, L., & Li, X. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400567s · Cited by 230

Human secreted tau increases amyloid-beta production

Bright, J., Hussain, S., Dang, V., Wright, S., Cooper, B., Byun, T., Ramos, C., Singh, A., Parry, G., Stagliano, N., et al. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.09.007 · Cited by 230

Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline

Koyama, A. K., Okereke, O. I., Yang, T., Blacker, D., Selkoe, D. J., & Grodstein, F. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1841 · Cited by 220

Regulation of Copper and Iron Homeostasis by Metal Chelators: A Possible Chemotherapy for Alzheimer’s Disease

Robert, A., Liu, Y., Nguyen, M., & Meunier, B. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00119 · Cited by 212

Autophagy in Alzheimer’s disease

Zare-shahabadi, A., Masliah, E., Johnson, G. V. W., & Rezaei, N. (2015) · Reviews in the Neurosciences · doi:10.1515/revneuro-2014-0076 · Cited by 204

Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the Aβ42Peptide

Sharma, A. K., Pavlova, S. T., Kim, J., Finkelstein, D., Hawco, N. J., Rath, N. P., Kim, J., & Mirica, L. M. (2012) · Journal of the American Chemical Society · doi:10.1021/ja210588m · Cited by 202

Imaging the progression of Alzheimer pathology through the brain

Smith, A. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082107399 · Cited by 202

The Second-Generation Active A Immunotherapy CAD106 Reduces Amyloid Accumulation in APP Transgenic Mice While Minimizing Potential Side Effects

Wießner, C., Wiederhold, K., Tissot, A. C., Frey, P., Danner, S., Jacobson, L. H., Jennings, G. T., Lüönd, R. M., Ortmann, R., Reichwald, J., et al. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.0293-11.2011 · Cited by 196

Tau-Centric targets and drugs in clinical development for the treatment of alzheimer's disease

Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Zecca, C., Barulli, M. R., Bellomo, A., Pilotto, A., et al. (2016) · BioMed Research International · doi:10.1155/2016/3245935 · Cited by 195

PET amyloid-beta imaging in preclinical Alzheimer's disease

Vlassenko, A. G., Benzinger, T. L. S., & Morris, J. C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.11.005 · Cited by 188

Imaging of β-amyloid plaques by near infrared fluorescent tracers: a new frontier for chemical neuroscience

Staderini, M., Martín, M. A., Bolognesi, M. L., & Menéndez, J. C. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00337c · Cited by 188

Visible–Near‐Infrared and Fluorescent Copper Sensors Based on Julolidine Conjugates: Selective Detection and Fluorescence Imaging in Living Cells

Maity, D., Manna, A. K., Karthigeyan, D., Kundu, T. K., Pati, S. K., & Govindaraju, T. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201101906 · Cited by 184

The Alzheimer’s therapeutic PBT2 promotes amyloid‐β degradation and GSK3 phosphorylation via a metal chaperone activity

Crouch, P. J., Savva, M. S., Hung, L. W., Donnelly, P. S., Mot, A. I., Parker, S. J., Greenough, M. A., Volitakis, I., Adlard, P. A., Cherny, R. A., et al. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07402.x · Cited by 183

Liposomal vaccines with conformation-specific amyloid peptide antigens define immune response and efficacy in APP transgenic mice

Muhs, A., Hickman, D. T., Pihlgren, M., Chuard, N., Giriens, V., Meerschman, C., der Auwera, I. V., LEUVEN, F. V., Sugawara, M., Weingertner, M.-C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703137104 · Cited by 182

The γ-secretase complex: from structure to function

Zhang, X., Li, Y., Xu, H., & Zhang, Y. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00427 · Cited by 179

The role of tau kinases in Alzheimer's disease.

Dolan, P. J., & Johnson, G. V. W. (2010) · PubMed · Cited by 178

Mitochondrial dysfunction - the beginning of the end in Alzheimer's disease? Separate and synergistic modes of tau and amyloid-β toxicity

Eckert, A., Schmitt, K., & Götz, J. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt74 · Cited by 177

The Ongoing Search for Small Molecules to Study Metal-Associated Amyloid-β Species in Alzheimer’s Disease

Savelieff, M. G., DeToma, A. S., Derrick, J. S., & Lim, M. H. (2014) · Accounts of Chemical Research · doi:10.1021/ar500152x · Cited by 174

Oleuropein and derivatives from olives as Tau aggregation inhibitors

Daccache, A., Lion, C. J., Sibille, N., Gérard, M., Slomianny, C., Lippens, G. M., & Cotelle, P. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.02.010 · Cited by 173

Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity

Du, W., Guo, J., Gao, M., Hu, S., Dong, X., Han, Y., Liu, F., Jiang, S., & Sun, Y. P. (2015) · Scientific Reports · doi:10.1038/srep07992 · Cited by 171

PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

Sabbagh, M. N., Agro, A., Bell, J. S., Aisen, P. S. S., Schweizer, E. E., & Galasko, D. R. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e318204b550 · Cited by 164

Liberation of Copper from Amyloid Plaques: Making a Risk Factor Useful for Alzheimer’s Disease Treatment

Geng, J., Li, M. C., Wu, L. J., Ren, J., & Qu, X. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3003813 · Cited by 153

Inhibition of Amyloid Fibril Formation by Peptide Analogues Modified with α‐Aminoisobutyric Acid

Gilead, S., & Gazit, E. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200353565 · Cited by 147

Safety, biodistribution, and dosimetry of 123I-IMPY: a novel amyloid plaque-imaging agent for the diagnosis of Alzheimer's disease.

Newberg, A. B., Wintering, N., Plößl, K., Hochold, J., Stabin, M. G., Watson, M., Skovronsky, D., Clark, C. M., Kung, M., & Kung, H. F. (2006) · PubMed · Cited by 143

Analyzing Amyloid Beta Aggregates with a Combinatorial Fluorescent Molecular Sensor

Hatai, J., Motiei, L., & Margulies, D. H. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.6b10809 · Cited by 137

Natural Tripeptide-Based Inhibitor of Multifaceted Amyloid β Toxicity

Rajasekhar, K., Madhu, C., & Govindaraju, T. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00175 · Cited by 136

Pyroglutamate-3 Amyloid-β Deposition in the Brains of Humans, Non-Human Primates, Canines, and Alzheimer Disease–Like Transgenic Mouse Models

Frost, J. L., Le, K. X., Cynis, H., Ekpo, E., Kleinschmidt, M., Palmour, R. M., Ervin, F. R., Snigdha, S., Cotman, C. W., Saido, T. C., et al. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.05.005 · Cited by 135

New developments on the role of NMDA receptors in Alzheimer's disease

Malinow, R. (2012) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2011.09.001 · Cited by 132

AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics

Eketjäll, S., Janson, J., Kaspersson, K., Bogstedt, A., Jeppsson, F., Fälting, J. M., Haeberlein, S. B., Kugler, A. R., Alexander, R. C., & Cebers, G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150834 · Cited by 132

Shedding light on tau protein aggregation: the progress in developing highly selective fluorophores

Verwilst, P., Kim, H. S., Kim, S., Kang, C., & Kim, J. S. (2018) · Chemical Society Reviews · doi:10.1039/c7cs00706j · Cited by 126

Beta-Secretase: Structure, Function, and Evolution

Venugopal, C., Demos, C., Rao, K. S. J., Pappolla, M. A., & Sambamurti, K. (2008) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152708784936626 · Cited by 125

Structure of Crenezumab Complex with Aβ Shows Loss of β-Hairpin

Ultsch, M., Li, B., Maurer, T., Mathieu, M., Adolfsson, O., Muhs, A., Pfeifer, A., Pihlgren, M., Bainbridge, T. W., Reichelt, M., et al. (2016) · Scientific Reports · doi:10.1038/srep39374 · Cited by 124

Amyloid Beta and Tau as Alzheimer’s Disease Blood Biomarkers: Promise From New Technologies

Lue, L., Guerra, A., & Walker, D. G. (2017) · Neurology and Therapy · doi:10.1007/s40120-017-0074-8 · Cited by 116

Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer's Disease: Prelude to a Clinical Trial

Davtyan, H., Ghochikyan, A., Petrushina, I., Hovakimyan, A., Davtyan, A., Poghosyan, A., Marleau, A. M., Movsesyan, N., Kiyatkin, A., Rasool, S., et al. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.4672-12.2013 · Cited by 112

A High Affinity Red Fluorescence and Colorimetric Probe for Amyloid β Aggregates

Rajasekhar, K., Narayanaswamy, N., Murugan, N. A., Kuang, G., Ågren, H., & Govindaraju, T. (2016) · Scientific Reports · doi:10.1038/srep23668 · Cited by 111

Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase I trial

Lacosta, A.-M., Pascual-Lucas, M., Pesini, P., Casabona, D., Pérez-Grijalba, V., Marcos-Campos, I., Sarasa, L., Canudas, J., Badi, H., Monleón, I., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0340-8 · Cited by 111

Stepping closer to treating Alzheimer’s disease patients with BACE1 inhibitor drugs

Yan, R. (2016) · Translational Neurodegeneration · doi:10.1186/s40035-016-0061-5 · Cited by 104

Stimuli-responsive colorimetric and NIR fluorescence combination probe for selective reporting of cellular hydrogen peroxide

Narayanaswamy, N., Narra, S., Nair, R. R., Saini, D. K., Kondaiah, P., & Govindaraju, T. (2016) · Chemical Science · doi:10.1039/c5sc03488d · Cited by 102

Advances in development of fluorescent probes for detecting amyloid-β aggregates

Xu, M., Ren, W., Tang, X.-C., Hu, Y., & Zhang, H. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2015.155 · Cited by 101

Aβ plaque-selective NIR fluorescence probe to differentiate Alzheimer's disease from tauopathies

Rajasekhar, K., Narayanaswamy, N., Murugan, N. A., Viccaro, K., Lee, H., Shah, K., & Govindaraju, T. (2017) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2017.06.030 · Cited by 100

Targeting Human Central Nervous System Protein Kinases: An Isoform Selective p38αMAPK Inhibitor That Attenuates Disease Progression in Alzheimer’s Disease Mouse Models

Roy, S. M., Grum-Tokars, V. L., Schavocky, J. P., Saeed, F., Staniszewski, A., Teich, A. F., Arancio, O., Bachstetter, A. D., Webster, S. J., Van Eldik, L. J., et al. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00002 · Cited by 99

Structure and Mechanism of Action of Tau Aggregation Inhibitors

Cisek, K. K., Cooper, G., Huseby, C. J., & Kuret, J. (2014) · Current Alzheimer Research · doi:10.2174/1567205011666141107150331 · Cited by 98

Molecular basis for mid-region amyloid-β capture by leading Alzheimer's disease immunotherapies

Crespi, G. A. N., Hermans, S. J., Parker, M. W., & Miles, L. A. (2015) · Scientific Reports · doi:10.1038/srep09649 · Cited by 96

Rationally Designed Peptidomimetic Modulators of Aβ Toxicity in Alzheimer's Disease

Rajasekhar, K., Suresh, S., Manjithaya, R. R., & Govindaraju, T. (2015) · Scientific Reports · doi:10.1038/srep08139 · Cited by 95

Restraining tumor necrosis factor-alpha by thalidomide prevents the Amyloid beta-induced impairment of recognition memory in mice

Alkam, T., Nitta, A., Mizoguchi, H., Saito, K., Seshima, M., Itoh, A., Yamada, K., & Nabeshima, T. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.12.014 · Cited by 94

Recent developments of protein kinase inhibitors as potential AD therapeutics

Tell, V., & Hilgeroth, A. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00189 · Cited by 92

Selective Brain-Targeted Antagonism of p38 MAPKα Reduces Hippocampal IL-1β Levels and Improves Morris Water Maze Performance in Aged Rats

Alam, J. J. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150277 · Cited by 91

The Anti-Inflammatory Role of Minocycline in Alzheimers Disease

Budni, J., Garcez, M. L., de Medeiros, J., Cassaro, E., Bellettini‐Santos, T., Mina, F., & Quevedo, J. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160819124206 · Cited by 90

Promoting Autophagic Clearance: Viable Therapeutic Targets in Alzheimer's Disease

Friedman, L. G., Qureshi, Y. H., & Yu, W. H. (2014) · Neurotherapeutics · doi:10.1007/s13311-014-0320-z · Cited by 89

Natural Compounds May Open New Routes to Treatment of Amyloid Diseases

Bieschke, J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0192-7 · Cited by 85

Two decades of new drug discovery and development for Alzheimer's disease

Liu, Z., Zhang, A., Sun, H. J., Han, Y., Kong, L. D., & Wang, X. (2017) · RSC Advances · doi:10.1039/c6ra26737h · Cited by 84

Methylene blue fails to inhibit Tau and polyglutamine protein dependent toxicity in zebrafish

van Bebber, F., Paquet, D., Hruscha, A., Schmid, B., & Haass, C. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.03.023 · Cited by 79

A Food and Drug Administration-approved Asthma Therapeutic Agent Impacts Amyloid β in the Brain in a Transgenic Model of Alzheimer Disease

Hori, Y., Takeda, S., Cho, H., Wegmann, S., Shoup, T. M., Takahashi, K., Irimia, D., Elmaleh, D. R., Hyman, B. T., & Hudry, E. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.586602 · Cited by 78

Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer’s Disease—Studies on Relation to Effective Target Occupancy

Hoffmann, T., Meyer, A., Heiser, U. F., Kurat, S., Böhme, L., Kleinschmidt, M., Bühring, K. U., Hutter‐Paier, B., Farcher, M., Demuth, H., et al. (2017) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.240614 · Cited by 77

Memogain is a Galantamine Pro-drug having Dramatically Reduced Adverse Effects and Enhanced Efficacy

Maelicke, A., Hoeffle-Maas, A., Ludwig, J., Maus, A. D. J., Samochocki, M., Jordis, U., & Koepke, A. K. E. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9269-5 · Cited by 73

The N-Methylated Peptide SEN304 Powerfully Inhibits Aβ(1–42) Toxicity by Perturbing Oligomer Formation

Amijee, H., Bate, C., Williams, A., Virdee, J. K., Jeggo, R., Spanswick, D. C., Scopes, D. I. C., Treherne, J. M., Mazzitelli, S., Chawner, R., et al. (2012) · Biochemistry · doi:10.1021/bi300415v · Cited by 72

Hybrid Multifunctional Modulators Inhibit Multifaceted Aβ Toxicity and Prevent Mitochondrial Damage

Rajasekhar, K., Mehta, K., & Govindaraju, T. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00033 · Cited by 69

Tabersonine Inhibits Amyloid Fibril Formation and Cytotoxicity of Aβ(1–42)

Kai, T., Zhang, L., Wang, X., Jing, A., Zhao, B., Yu, X., Zheng, J., & Zhou, F. (2015) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00015 · Cited by 66

In-vivo histamine H3 receptor antagonism activates cellular signaling suggestive of symptomatic and disease modifying efficacy in Alzheimer’s disease

Bitner, R. S., Markosyan, S., Nikkel, A. L., & Brioni, J. D. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.10.026 · Cited by 65

Comparison of New Tau PET-Tracer Candidates With [ 18 F]T808 and [ 18 F]T807

Declercq, L., Celen, S., Lecina, J., Ahamed, M., Tousseyn, T., Moechars, D., Alcázar, J., Ariza, M., Fierens, K., Bottelbergs, A., et al. (2016) · Molecular Imaging · doi:10.1177/1536012115624920 · Cited by 63

β-Hairpin mimics containing a piperidine–pyrrolidine scaffold modulate the β-amyloid aggregation process preserving the monomer species

Pellegrino, S., Tonali, N., Erba, E., Kaffy, J., Taverna, M., Contini, A., Taylor, M., Allsop, D., Gelmi, M. L., & Ongeri, S. (2016) · Chemical Science · doi:10.1039/c6sc03176e · Cited by 63

Inhibition of Alzheimer's amyloid-β peptide aggregation and its disruption by a conformationally restricted α/β hybrid peptide

Paul, A., Nadimpally, K. C., Mondal, T., Thalluri, K., & Mandal, B. (2014) · Chemical Communications · doi:10.1039/c4cc09063b · Cited by 61

Rationally Designed Peptoids Modulate Aggregation of Amyloid-Beta 40

Turner, J. P., Lutz-Rechtin, T. M., Moore, K. A., Rogers, L., Bhave, O., Moss, M. A., & Servoss, S. L. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn400221u · Cited by 55

Receptor for Advanced Glycation end Products: Its Role in Alzheimer‘s Disease and other Neurological Diseases

Lue, L., Walker, D. G., Jacobson, S. A., & Sabbagh, M. N. (2009) · Future Neurology · doi:10.2217/14796708.4.2.167 · Cited by 54

Designed Glycopeptidomimetics Disrupt Protein–Protein Interactions Mediating Amyloid β-Peptide Aggregation and Restore Neuroblastoma Cell Viability

Kaffy, J., Brinet, D., Soulier, J. L., Correia, I., Tonali, N., Fabiana, F. K., Iacone, Y., Hoffmann, A. R. F., Khemtémourian, L., Crousse, B., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01629 · Cited by 54

A new roadmap for drug development for Alzheimer's disease

Becker, R. E., Greig, N. H., Giacobini, E., Schneider, L. S. S., & Ferrucci, L. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3842-c2 · Cited by 52

Crystal structure reveals conservation of amyloid-β conformation recognized by 3D6 following humanization to bapineuzumab

Feinberg, H., Saldanha, J. W., Diep, L., Goel, A. S., Widom, A., Veldman, G. M., Weis, W. I., Schenk, D., & Basi, G. S. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt261 · Cited by 52

Biomarkers in Alzheimer’s Disease Analysis by Mass Spectrometry-Based Proteomics

Liu, Y., Qing, H., & Deng, Y. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15057865 · Cited by 51

SPECT Imaging Agents for Detecting Cerebral β-Amyloid Plaques

Ono, M., & Saji, H. (2011) · International Journal of Molecular Imaging · doi:10.1155/2011/543267 · Cited by 51

An effective treatment for Alzheimer's disease must consider both amyloid and tau

Lansdall, C. J. (2014) · Bioscience Horizons The International Journal of Student Research · doi:10.1093/biohorizons/hzu002 · Cited by 46

Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models

Brendel, M., Jaworska, A. M., Probst, F., Overhoff, F., Korzhova, V., Lindner, S., Carlsen, J., Bartenstein, P., Harada, R., Kudo, Y., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.163493 · Cited by 45

Vaccination against Alzheimer disease

Fettelschoss‐Gabriel, A., Zabel, F., & Bachmann, M. F. (2014) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.28183 · Cited by 39

Inhibition of Cu‐Amyloid‐β by using Bifunctional Peptides with β‐Sheet Breaker and Chelator Moieties

Jensen, M., Canning, A., Chiha, S., Bouquerel, P., Pedersen, J. T., Østergaard, J., Cuvillier, O., Sasaki, I., Hureau, C., & Faller, P. (2012) · Chemistry - A European Journal · doi:10.1002/chem.201103546 · Cited by 38

Histidine‐Rich Oligopeptides To Lessen Copper‐Mediated Amyloid‐β Toxicity

Caballero, A. B., Terol‐Ordaz, L., Espargaró, A., Vázquez, G., Nicolás, E., Sabaté, R., & Gámez, P. (2016) · Chemistry - A European Journal · doi:10.1002/chem.201600286 · Cited by 30

Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease

Lambracht‐Washington, D., & Rosenberg, R. N. (2012) · Translational Neuroscience · doi:10.2478/s13380-012-0037-6 · Cited by 23

Synthesis of Hybrid Cyclic Peptoids and Identification of Autophagy Enhancer

Rajasekhar, K., Narayanaswamy, N., Mishra, P., Suresh, S., Manjithaya, R. R., & Govindaraju, T. (2013) · ChemPlusChem · doi:10.1002/cplu.201300343 · Cited by 23

Novel PET/SPECT Probes for Imaging of Tau in Alzheimer’s Disease

Watanabe, H., Ono, M., & Saji, H. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/124192 · Cited by 22

P1‐279: NIC5‐15 as a treatment for Alzheimer's: Safety, pharmacokinetics and clinical variables

Grossman, H. T., Marzloff, G. E., Luo, X., LeRoith, D., Sano, M. C., & Pasinetti, G. M. (2009) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2009.04.287 · Cited by 17

Modulation of autophagy as a therapeutic target for Alzheimer’s disease

Steele, J., Fan, E. Y., Kelahmetaglu, Y., Tian, Y., & Bustos, V. (2013) · Postdoc Journal · doi:10.14304/surya.jpr.v1n2.3 · Cited by 16

P2‐003: Clinical Trial Design of Cread: A Randomized, Double‐Blind, Placebo‐Controlled, Parallel‐Group Phase 3 Study to Evaluate Crenezumab Treatment in Patients with Prodromal‐To‐Mild Alzheimer’s Disease

Blaettler, T., Smith, J., Smith, J. P., Paul, R. H., Asnaghi, V., Fuji, R. N., Quartino, A. L., Honigberg, L. A., Rabbia, M. A., Yule, S., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.1207 · Cited by 15

Diagnostic methods and biomarkers for Alzheimer’s disease

Bagyinszky, E., Youn, Y. C., An, S. S. A., & Kim, S. (2014) · Toxicology and Environmental Health Sciences · doi:10.1007/s13530-014-0198-5 · Cited by 13

O1‐10‐06: Results From a First‐in‐Human Study with the Bace Inhibitor CNP520

Ufer, M., Rouzade‐Dominguez, M., Huledal, G., Pezous, N., Avraméas, A., David, O., Kretz, S., Kucher, K., Neumann, U., Cha, J., et al. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.351 · Cited by 9

[P1–043]: ELENBECESTAT, A NOVEL ORAL BACE INHIBITOR, HAS NO CLINICALLY MEANINGFUL EFFECT ON QTC INTERVAL UP TO A SUPRATHERAPEUTIC DOSE OF 200 MG

Lai, R. Y. K., Darpö, B., Dayal, S., Hall, N., Chang, M., Albala, B., Ferry, J., & Rege, B. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.110 · Cited by 7

Immune-modified response criteria — an iterative learning process?

Ott, P. A. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.36 · Cited by 6

[P1–042]: PLASMA PHARMACOKINETICS AND PHARMACODYNAMICS OF SOLANEZUMAB IN MILD AND MODERATE AD PATIENTS

Willis, B. A., Ferguson‐Sells, L. R., Chua, L., Siemers, E., Dean, R. A., Lachno, D. R., Carlson, C. D., Hake, A. M., Hoffmann, V. P., & Friedrich, S. W. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.06.109 · Cited by 5

O4–05–01: A first‐in‐human study of BAN2401, a novel monoclonal antibody against beta‐amyloid protofibrils

Lai, R. Y. K., Logovinsky, V., Kaplow, J. M., Gu, K., Yu, Y., Möller, C., NAVIA, B. A., Swanson, C. J., Lannfelt, L., & Satlin, A. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.04.358 · Cited by 4

Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer’s Disease

Khan, S., Barve, K. H., & Kumar, M. S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200528142429 · Cited by 820

Biomolecules-derived biomaterials

Datta, L. P., Manchineella, S., & Govindaraju, T. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.119633 · Cited by 187

Metallobiology and therapeutic chelation of biometals (copper, zinc and iron) in Alzheimer’s disease: Limitations, and current and future perspectives

Fasae, K. D., Abolaji, A. O., Faloye, T. R., Odunsi, A., Oyetayo, B. O., Enya, J. I., Rotimi, J. A., Akinyemi, R., Whitworth, A. J., & Aschner, M. (2021) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2021.126779 · Cited by 161

Mitochondrial dysfunctions, oxidative stress and neuroinflammation as therapeutic targets for neurodegenerative diseases: An update on current advances and impediments

Rehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130

Antioxidant Berberine-Derivative Inhibits Multifaceted Amyloid Toxicity

Rajasekhar, K., Samanta, S., Bagoband, V., Murugan, N. A., & Govindaraju, T. (2020) · iScience · doi:10.1016/j.isci.2020.101005 · Cited by 100

Chapter 1. Alzheimer's is a Multifactorial Disease

Samanta, S., Ramesh, M., & Govindaraju, T. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839162732-00001 · Cited by 37

The Pathophysiology of Alzheimer’s Disease

Selkoe, D. J. (2000) · Humana Press eBooks · doi:10.1007/978-1-59259-005-6_4 · Cited by 9

Multipronged diagnostic and therapeutic strategies for Alzheimer's disease

Ramesh, M., & Govindaraju, T. (2022) · Chemical Science · doi:10.1039/d2sc03932j · Cited by 87

Next Generation Drugs in Alzheimer's Disease Treatment: From Benchtop to Bedside

(2013) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781608057221113010005

Advances in the treatment of Alzheimer’s disease

Goceroglu, R. T., & Hacımüftüoğlu, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1819165 · Cited by 1